Recombinant fragmented human-derived III-type collagen as well as preparation method and application thereof
By removing the propeptide sequence and optimizing the coding gene, combined with the E. coli expression system, rapid purification and high biological activity of recombinant fragmented human type III collagen are achieved, solving the complex problem of recombinant collagen synthesis in the existing technology, and expanding Its application in multiple fields.
Patent Information
- Application Number
- CN202411176341.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, the synthesis of recombinant human type III collagen is complex and difficult to achieve activity, which limits its application in the fields of medicine, health care, etc.
Recombinant fragmented human type III collagen, by removing the propeptide sequence and retaining the necessary endopeptide for fiber formation, combining the E. coli expression system, optimized the coding gene sequence, and using His*6-SUMO prosthetic tag and Ulp1 protease Rapid purification to reduce expression pressure and heteroprotein content.
The soluble expression and rapid purification of recombinant fragmented human type III collagen has been achieved, expanding its application in cell experiments, wound repair, medical cosmetic plastic surgery and cosmetics fields, and is non-toxic to cells and has high biological activity.
Smart Images

Figure CN118955688A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a recombinant fragmented human type III collagen and a preparation method and application thereof, belonging to the technical field of bioengineering. Background Art
[0002] Collagen is the main protein in the human extracellular matrix. It is abundant in the human body, accounting for one-third of human protein and three-quarters of the dry weight of the skin. It plays a key connecting role in bones, skin, and joints. In addition to its structural role, collagen can also interact with various macromolecules such as integrins, decorative proteins, fibronectin, heparin, and matrix metalloproteinases, and is very important in regulating tissue regeneration.
[0003] Type III collagen is mainly distributed in the reticular structure of the skin, blood vessel walls and most tissues, which makes organs elastic and maintains organ integrity. It accounts for about 5-20% of the total collagen content in the human body. Type III collagen also exists in adult cartilage and is the main structural component of hollow organs such as large blood vessels and intestines. It has a strong correlation with type I collagen in many other tissues. Type III collagen is also widely distributed in the cortex, but is concentrated on the surface of the Haversian canal and the bone-periosteum interface.
[0004] All members of the collagen family are right-handed triple helical structures composed of three left-handed polypeptide α chains, while human type III collagen is a homotrimer composed of three identical α chains, encoded by the COL3A1 gene. The triple helical conformation is a characteristic of all fibrous collagens, because in a sequence of approximately 1,000 amino acids, one glycine is present in every three amino acids. This (Gly-Xaa-Yaa)n sequence is repeated 343 times in type III collagen molecules. Proline or hydroxyproline is often found at the X- and Y-positions, making the triple helical structure stable. Recombinant collagen has advantages that natural collagen does not have, including processability, no viral risks, and low rejection reactions, without changing the functional properties of natural collagen, and can be mass-produced through genetic engineering, making it a research hotspot for the design and synthesis of collagen. Human recombinant type III collagen (hCOL3) has strong water solubility and high biological activity, and has important application value in medicine, health care, nutrition, etc. However, the synthesis of human full-length type III collagen is relatively complex and recombinant collagen is difficult to be active, which greatly limits its application. Summary of the invention
[0005] In order to address at least one problem existing in the above-mentioned prior art, the present invention provides a recombinant fragmented human type III collagen and a preparation method and application thereof, which can be quickly purified, and the purified collagen is non-toxic to cells, thereby expanding its application.
[0006] In order to achieve the above-mentioned purpose, the present invention adopts the following technical scheme: a recombinant fragmented human type III collagen, the amino acid sequence of which is shown in SEQ ID NO.3.
[0007] Preferably, the recombinant fragmented human type III collagen does not contain propeptides but includes terminal peptides necessary for fiber formation. The recombinant fragmented human type III collagen is obtained by splicing and recombining sequence fragments that retain the functional domains of natural collagen, the amino acid sequence as shown in SEQ ID NO.1 and the amino acid sequence as shown in SEQ ID NO.2, and redesigning and synthesizing them.
[0008] A recombinant fragmented human type III collagen encoding gene, which encodes the above-mentioned recombinant fragmented human type III collagen.
[0009] Preferably, the nucleotide sequence of the encoding gene is shown as SEQ ID NO.4.
[0010] Preferably, the nucleotide sequence shown in SEQ ID NO.4 is a codon-optimized sequence adapted to the E. coli expression system.
[0011] A recombinant fragmented human type III collagen expression vector comprises the above-mentioned recombinant fragmented human type III collagen encoding gene.
[0012] Preferably, the plasmid vector of the recombinant expression vector is pRSFDuet-1.
[0013] Preferably, the construction method of the recombinant expression vector is as follows: first insert the His*6-SUMO soluble tag into the plasmid vector pRSFDuet-1 Nco I and Bm I restriction site, and then the recombinant fragmented human type III collagen encoding gene was inserted into the plasmid vector pRSFDuet-1 Bm I and Sal I restriction site to obtain a recombinant expression vector.
[0014] A recombinant Escherichia coli engineered bacterium contains the above-mentioned recombinant fragmented human type III collagen coding gene or the above-mentioned recombinant fragmented human type III collagen expression vector.
[0015] Preferably, the host bacteria of the recombinant Escherichia coli engineered bacteria is Escherichia coli.
[0016] Preferably, the Escherichia coli is Escherichia coli ER2566.
[0017] Preferably, the above-mentioned fragmented human type III collagen recombinant Escherichia coli engineering bacteria are used in the preparation of recombinant fragmented human type III collagen.
[0018] A method for preparing recombinant fragmented human type III collagen is prepared by the following process: synthesizing and amplifying the nucleotide sequence of the coding gene as shown in SEQ ID NO.4, using pRSFDuet-1 as a plasmid vector, constructing a recombinant fragmented human type III collagen expression vector, and transferring it into recipient cells and screening it, culturing the engineered bacteria, inducing expression and separating it, and then purifying it to obtain the recombinant fragmented human type III collagen.
[0019] Preferably, the recipient cell comprises an Escherichia coli ER2566 expression strain.
[0020] Preferably, the method of inducing expression comprises IPTG induction.
[0021] Preferably, the purification comprises nickel affinity column chromatography, Ulp1 protease cleavage and secondary nickel affinity column chromatography.
[0022] Preferably, the method for preparing the recombinant fragmented human type III collagen comprises the following specific steps: (1) Cloning the recombinant fragmented human type III collagen coding gene: synthesizing the nucleotide sequence encoding the recombinant fragmented human type III collagen single chain as shown in SEQ ID NO.4, designing PCR primers, and amplifying the DNA fragment encoding the recombinant fragmented human type III collagen single chain; (2) Construction of recombinant fragmented human type III collagen expression vector: pRSFDuet-1 was used as a plasmid vector. Nco I and Bam Insert His*6-SUMO solubility tag between HI restriction sites. Bam HI and Sal Insert the above-mentioned recombinant fragmented human type III collagen coding gene SEQ ID NO.4 between the restriction sites I; (3) Construction of fragmented human type III collagen recombinant Escherichia coli engineering bacteria: The recombinant fragmented human type III collagen expression vector constructed above was transferred into Escherichia coli ER2566 cells for screening; (4) Cultivation, induction of expression, and separation: The above-mentioned fragmented human type III collagen recombinant Escherichia coli engineering bacteria were inoculated and cultured until the OD600 was 1.2. After IPTG induction of expression, the cells were collected by centrifugation, resuspended, broken, and the supernatant was collected by centrifugation to obtain a crude recombinant fragmented human type III collagen solution; (5) Purification: The crude recombinant fragmented human type III collagen solution is filtered and chromatographed on a nickel affinity column, and the recombinant fragmented human type III collagen is collected and cleaved by Ulp1 protease, filtered, and chromatographed on a nickel affinity column for the second time to obtain the recombinant fragmented human type III collagen.
[0023] The recombinant fragmented human type III collagen can be used as a biological material and applied to cell experiments.
[0024] An application of the above-mentioned recombinant fragmented human type III collagen in the fields of wound repair materials, medical cosmetology and plastic surgery, and cosmetics.
[0025] Beneficial effects of the present invention: 1. The present invention selects a recombinant human type III collagen structural fragment that does not contain a propeptide but includes a terminal peptide necessary for fiber formation, and the fragment retains the sequence of the type III collagen functional domain. By removing the propeptide sequence, the molecular weight of the recombinant protein is reduced, the expression pressure of the strain is reduced, and the soluble expression of recombinant fragmented human type III collagen is successfully achieved.
[0026] 2. According to the expression characteristics of Escherichia coli, the present invention performs codon optimization on the nucleotide sequence encoding recombinant fragmented human type III collagen, so that the nucleotide sequence encoding recombinant fragmented human type III collagen is more suitable for the Escherichia coli expression system.
[0027] 3. The present invention introduces a His*6-SUMO solubility-promoting tag, and the SUMO protein can be cleaved by its protease Ulp1 through a specific structure recognition method, so that the recombinant fragmented human type III collagen can be quickly purified through nickel column affinity chromatography, enzymatic cleavage (Ulp1 protease), and secondary affinity chromatography.
[0028] 4. The pRSFDuet-1 used in the present invention is an expression vector that can continuously secrete and express collagen in the life activities of the engineered bacteria. The fermentation process is simple and contains less impurities, providing an advantageous strain for large-scale fermentation production. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 This is the agarose gel electrophoresis diagram of the DNA fragment of the recombinant fragmented human type III collagen hCOL3 in Example 1.
[0030] Figure 2 This is the plasmid map of the recombinant expression vector pRSFDuet-1-hCOL3 in Example 2.
[0031] Figure 3 This is the protein electrophoresis diagram of the recombinant fragmented human type III collagen hCOL3 obtained by separation and purification in Example 4.
[0032] Figure 4 This is the live-dead staining imaging of RAW264.7 and WB-F344 cells in the recombinant fragmented human type III collagen hCOL3 cell activity and toxicity experiment in Example 5. DETAILED DESCRIPTION
[0033] The technical scheme in the implementation of the present invention is clearly and completely described below in conjunction with the accompanying drawings. The described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If the specific conditions are not specified in the embodiments, they are carried out according to the conditions recommended by the normal conditions or the manufacturers. If the manufacturers are not specified in the reagents, instruments, and components used, they are all conventional products that can be purchased commercially.
[0034] The Escherichia coli ER2566 and plasmid vector pRSFDuet-1 selected in the present invention are both strains and vectors that can be directly purchased.
[0035] The culture medium involved in the present invention is as follows: LB liquid medium: 10 g / L peptone, 5 g / L yeast powder, 10 g / L NaCl.
[0036] LB solid medium: Add 2% agar to LB liquid medium.
[0037] Example 1 Cloning of the gene encoding recombinant fragmented human type III collagen hCOL3 The specific steps are as follows: (1) Gene design and synthesis: Based on the amino acid sequence of human type III collagen as shown in SEQ ID NO.3, the sequence fragments of the natural collagen functional domain: the amino acid sequence as shown in SEQ ID NO.1 and the amino acid sequence as shown in SEQ ID NO.2 were spliced and designed using SnapGene software. The gene sequence does not contain the propeptide but includes the terminal peptide necessary for fiber formation. In view of the codon preference of Escherichia coli and the AT content of the DNA sequence, the online codon optimization software was used to change the corresponding original recombinant human type III collagen codon bases to the bases preferred by Escherichia coli without changing the protein coding sequence. The optimized gene sequence was handed over to Hangzhou Youkang Biotechnology Co., Ltd. to synthesize the corresponding nucleotide sequence based on the amino acid sequence; the nucleotide sequence of the corresponding optimized gene sequence is shown in SEQ ID NO.4; SEQ ID NO.1: MSYDVKSGVAVGGLAGYPGPAGPPGPPGPPGTSGHPGSPGSPGYQGPPGEPGQAGPSGPPGPPGAIGPSGPAGKDGESGRPGRPGERGLPGPPGIKGPAGIPGFPGMKGHRGFDGRNGEKGETGAPGLKGENGLPGENGAPGPMGPRGAPGERGRPGLPGAAGARGNDGARGSDGQPGPPGPPGTAGFPGSPGAKGEVGPAGSPGSNGAPGQRGEPGPQGHAG SEQ ID NO.2: PPGPVGPAGKSGDRGESGPAGPAGAPGPAGSRGAPGPQGPRGDKGETGERGAAGIKGHRGFPGNPGAPGSPGPAGQQGAIGSPGPAGPRGPVGPSGPPGKDGTSGHPGPIGPPGPRGNRGERGSEGSPGHPGQPGPPGPPGAPGPCCGGVGAAAIAGIGGEKAGGFAPYY SEQ ID NO.3 MSYDVKSGVAVGGLAGYPGPAGPPGPPGPPGTSGHPGSPGSPGYQGPPGEPGQAGPSGPPGPPGAIGPSGPAGKDGESGRPGRPGERGLPGPPGIKGPAGIPGFPGMKGHRGFDGRNGEKGETGAPGLKGENGLPGENGAPGPMGPRGAPGERGRPGLPGAAGARGNDGARGSDGQPGPPGPPGTAGFPGSPGAKGEVGPAGSPGSNGAPGQRGEPGPQGHAGPPGPVGPAGKSGDRGESGPAGPAGAPGPAGSRGAPGPQGPRGDKGETGERGAAGIKGHRGFPGNPGAPGSPGPAGQQGAIGSPGPAGPRGPVGPSGPPGKDGTSGHPGPIGPPGPRGNRGERGSEGSPGHPGQPGPPGPPGAPGPCCGGVGAAAIAGIGGEKAGGFAPYY SEQ ID NO.4:
[0038] (2) Gene cloning Design specific primers and use PCR to amplify the recombinant fragmented human type III collagen hCOL3 single-stranded DNA fragment. The designed primer sequences are as follows: RSFD-F, the nucleotide sequence is shown in SEQ ID NO.5, RSFD-R, the nucleotide sequence is shown in SEQ ID NO.6; Recol-F-1 / 2, the nucleotide sequence is shown in SEQ ID NO.7, Recol-R-1 / 2, the nucleotide sequence is shown in SEQ ID NO.8; Recol-F-2 / 2, the nucleotide sequence is shown in SEQ ID NO.9, Recol-R-2 / 2, the nucleotide sequence is shown in SEQ ID NO.10; SEQ ID NO.5: GTATTATTGCTTTCTGTAAGTCGACAAGCTTGC SEQ ID NO.6: CATCATGGATCCACCAATCTGTCCTTGTG SEQ ID NO.7: GGTGGATCCATGATGAGCTACGACGTGAAGAGC SEQ ID NO.8 CGGCGGACCCGCATGCCCTTGCGGACCT SEQ ID NO.9: CATGCGGGTCCGCCGGGTCCTGTGGGCCCGGCA SEQ ID NO.10: AGAAAGCAATAATACGGTGCAAAACC The PCR amplification program was set as follows: first, pre-denaturation at 95°C for 5 min; then 30 cycles of denaturation at 95°C for 30 s, annealing at 58°C for 30 s, extension at 72°C for 25 s, and insulation at 4°C.
[0039] Analysis: The PCR products obtained above were detected by 0.8% agarose gel electrophoresis. Figure 1 As shown, the target band size is 1209 bp.
[0040] Example 2 Construction of recombinant fragmented human type III collagen hCOL3 expression vector The specific steps are as follows: The encoding gene SEQ ID NO.4 of the recombinant fragmented human type III collagen hCOL3 obtained in Example 1 and the plasmid vector pRSFDuet-1 were digested by enzymes: Nco I and Bam The His*6-SUMO solubility tag was inserted between the HI restriction sites and then in the pRSFDuet-1 expression vector. Bm I and Sal The coding gene sequence shown in SEQ ID NO.4 obtained in Example 1 was inserted between the restriction sites I to obtain the recombinant expression vector pRSFDuet-1-hCOL3.
[0041] Analysis: The recombinant fragmented human type III collagen hCOL3 expression vector pRSFDuet-1-hCOL3 Figure 2 Plasmid maps are shown.
[0042] Example 3 Construction of recombinant Escherichia coli producing fragmented human type III collagen hCOL3 The specific steps are as follows: 1 μg of the recombinant expression vector pRSFDuet-1-hCOL3 obtained in Example 2 was transformed into 100 μL of E. coli ER2566 competent cells and screened to obtain the recombinant E. coli engineered bacteria: E. coli / pRSFDuet-1-hCOL3.
[0043] Example 4 Cultivation, expression, separation and purification of recombinant fragmented human type III collagen hCOL3 The specific steps are as follows: (1) Cultivation: The recombinant Escherichia coli engineered bacteria: E. coli / pRSFDuet-1-hCOL3 prepared in Example 3 was inoculated into 10 mL of LB liquid culture medium containing 50 µg / mL kanamycin sulfate, and cultured overnight at 37°C and 200 rpm to prepare a seed solution; (2) Inducing expression: The prepared seed solution was transferred to 100 mL of LB liquid medium containing 50 µg / mL kanamycin sulfate at an inoculum volume of 2% (v / v), and cultured in a shaking incubator at 37°C and 220 rpm until the OD600 reached about 1.2. IPTG was then added to induce expression. During expression, low temperature induction was performed overnight at 20°C for 18 h to obtain a fermentation broth. (3) Separation: The fermentation broth was centrifuged at 8000 × g and 4°C for 5 min to obtain cell bodies, and the cells were washed three times and resuspended in 10 mL of disodium hydrogen phosphate-sodium dihydrogen phosphate buffer (pH 7.0). The resuspended cells were then disrupted with an ultrasonic disruptor in an ice bath for 30 min, centrifuged for 30 min (8000 × g, 4°C), and the supernatant was collected, which was the crude recombinant fragmented human type III collagen hCOL3 solution. (4) Purification: Supernatant Pass through 0.22µm filter filter , and then further loaded onto a 1 mL nickel affinity column, which was pre-equilibrated with 30 mL equilibration buffer (20 mM Tris and 500 mM NaCl, pH 7.4), and then the elution buffer (20 mM Tris, 500 mM NaCl and 500 mM imidazole, pH 7.4) was used to elute the unbound proteins and recombinant fragmented human type III collagen hCOL3 using a linear gradient; the collected target protein was cleaved with Ulp1 protease overnight and filtered with a 0.22 μm filter membrane, and then the enzymatically cleaved recombinant fragmented human type III collagen hCOL3 sample was replaced into a low imidazole buffer through a desalting column, and then the nickel column was re-hung for secondary nickel affinity column chromatography and the target protein was eluted with high imidazole, during which the flow-through and elution samples were collected.
[0044] Analysis: The above flow-through and elution samples were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Figure 3 As shown, the results showed that there was an obvious band at 51 kDa, proving that the recombinant fragmented human type III collagen hCOL3 was expressed.
[0045] Example 5 Cellular activity and toxicity detection of recombinant fragmented human type III collagen hCOL3 According to the instructions of the Calcein / PI cell activity and cytotoxicity detection kit produced by Bio-Time, taking RAW 264.7 cells and WB-F344 cells as examples, the following steps were used to detect the effect of the recombinant fragmented human type III collagen hCOL3 obtained in Example 4 on the activity of the cells.
[0046] The specific steps are as follows: (1) Prepare Calcein AM / PI working solution according to the instructions (prepare immediately before use); (2) The recombinant fragmented human type III collagen hCOL3 obtained in Example 4 was spread on a 96-well plate, and 50 μL of 3.2 mg / mL was added to each well. At the same time, 50 μL of PBS buffer was added to another well as a negative control (NC). Two wells were grouped together and left overnight. (3) The next day, add 1 μL of cell suspension with a concentration of 1×106 cells / mL to each experimental well, then add 100 μL of complete culture medium and culture in a cell CO2 incubator for 15-17 h. (4) Add an appropriate volume of Calcein AM / PI detection working solution, usually 100 μL per well of a 96-well plate and 250 μL per well of a 24-well plate, and incubate at 37 °C in the dark for 30 min. (5) After incubation, the cell status was analyzed using a high-content imaging system with 25 fields per well.
[0047] Analysis: The results of the above tests are as follows Figure 4 As shown, Figure 4 A is the live-dead cell staining analysis of RAW 264.7 cells under different conditions. Figure 4 B is the live-dead cell staining analysis of WB-F344 cells under different conditions; Figure 4 A and Figure 4 As can be seen in B, the proportions of the two types of cell activities in the control group NC in the cell non-toxicity test are consistent, and the live and dead conditions of the two types of cells cultured after plating recombinant fragmented human type III collagen hCOL3 are basically the same, and the cell activity proportions are basically the same as those of the control group NC, with no significant difference (t test p>0.05, ns), that is, recombinant fragmented human type III collagen hCOL3 is non-toxic to cells, has excellent activity, and can be used as a biomaterial for cell experiments.
[0048] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the spirit and essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.
[0049] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.
Claims
1. A recombinant fragmented human type III collagen, characterized in that: Its amino acid sequence is shown in SEQ ID NO.
3.
2. The recombinant fragmented human type III collagen according to claim 1, characterized in that: It does not contain propeptides but includes terminal peptides necessary for fiber formation, and is obtained by splicing and recombining the amino acid sequence fragments of human type III collagen shown in SEQ ID NO.1 and SEQ ID NO.
2.
3. A recombinant fragmented human type III collagen encoding gene, characterized in that: It encodes the recombinant fragmented human type III collagen described in claim 1.
4. A recombinant fragmented human type III collagen encoding gene according to claim 3, characterized in that: The nucleotide sequence of the coding gene is shown in SEQ ID NO.
4.
5. A recombinant fragmented human type III collagen encoding gene according to claim 4, characterized in that: The nucleotide sequence shown in SEQ ID NO.4 is a codon-optimized sequence adapted to the E. coli expression system.
6. A recombinant fragmented human type III collagen expression vector, characterized in that: It includes the recombinant fragmented human type III collagen encoding gene as described in claim 3.
7. The recombinant fragmented human type III collagen expression vector according to claim 6, characterized in that: The plasmid vector of the recombinant expression vector is pRSFDuet-1.
8. The recombinant fragmented human type III collagen expression vector according to claim 7, characterized in that: The construction method of the recombinant expression vector is as follows: insert the His*6-SUMO lytic tag into the plasmid vector pRSFDuet-1 Nco I and Bm I restriction site, the recombinant fragmented human type III collagen encoding gene of claim 3 is inserted into the plasmid vector pRSFDuet-1 Bm I and Sal I restriction site to obtain a recombinant expression vector.
9. A recombinant Escherichia coli engineered bacterium, characterized in that: Contains the recombinant fragmented human type III collagen encoding gene as described in claim 3 or the recombinant fragmented human type III collagen expression vector as described in claim 6.
10. The recombinant Escherichia coli engineering bacterium according to claim 7, characterized in that: The host bacteria of the fragmented human type III collagen recombinant Escherichia coli engineering bacteria is Escherichia coli; the Escherichia coli is Escherichia coli ER2566.
11. The recombinant Escherichia coli engineering bacterium according to claim 9, characterized in that: Application in the preparation of recombinant fragmented human type III collagen.
12. A method for preparing recombinant fragmented human type III collagen, characterized in that: The specific steps of the preparation method are as follows: (1) Cloning the recombinant fragmented human type III collagen coding gene: synthesizing the nucleotide sequence encoding the recombinant fragmented human type III collagen single chain as shown in SEQ ID NO.4, designing PCR primers, and amplifying the DNA fragment encoding the recombinant fragmented human type III collagen single chain; (2) Construction of recombinant fragmented human type III collagen expression vector: pRSFDuet-1 was used as a plasmid vector. Nco I and Bam Insert His*6-SUMO solubility tag between HI restriction sites. Bam HI and Sal Insert the above-mentioned recombinant fragmented human type III collagen coding gene SEQ ID NO.4 between the restriction sites I; (3) Construction of fragmented human type III collagen recombinant Escherichia coli engineering bacteria: The recombinant fragmented human type III collagen expression vector constructed above was transferred into Escherichia coli ER2566 cells for screening; (4) Cultivation, induction of expression, and separation: The above-mentioned fragmented human type III collagen recombinant Escherichia coli engineering bacteria were inoculated and cultured until the OD600 was 1.
2. After IPTG induction of expression, the cells were collected by centrifugation, resuspended, broken, and the supernatant was collected by centrifugation to obtain a crude recombinant fragmented human type III collagen solution; (5) Purification: The crude recombinant fragmented human type III collagen solution is filtered and chromatographed on a nickel affinity column, and the recombinant fragmented human type III collagen is collected and cleaved by Ulp1 protease, filtered, and chromatographed on a nickel affinity column for the second time to obtain the recombinant fragmented human type III collagen.
13. A use of the recombinant fragmented human type III collagen according to claim 1, characterized in that: It can be used as a biomaterial and applied in cell experiments.
Citation Information
Patent Citations
Recombinant (X VII) type collagen with triple helix structure and application of recombinant (X VII) type collagen
CN118240066A
Recombinant human-derived III-type collagen capable of promoting cell migration and preparation method and application of recombinant human-derived III-type collagen
CN118772263A
Collagen-binding physiologically active polypeptide
CN1347456A
A transparent conductive substrate and a double-side photolithographic method using the same
KR1020240031124A
Cited By
Anti-HPV (human papillomavirus) infection recombinant III-type human collagen peptide as well as preparation method and application thereof
CN119306819A
Recombinant human collagen type III peptide against HPV infection and preparation method and application thereof
CN119306819B
Recombinant III-type collagen with high thermal stability and high transdermal absorption and application thereof
CN119798465A
Expression cassette and method for producing humanized triple helix collagen by using expression cassette
CN120384093A
A recombinant collagen, freeze-dried fiber and its preparation method
CN122668239A
